Stuart Therapeutics Announces First Patient, First Visit in its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease
Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced the First Patient First Visit (FPFV) for the company’s Phase 3 clinical trial of ST-100 (vezocolmitide),…
Dry Eye Disease: The Digital Age Epidemic and the Solution by Dr. Agarwals Eye Hospital
Dry Eye Disease is rapidly becoming an epidemic in the digital age, particularly in India’s leading IT centers like Mumbai, where screen-centric lifestyles are prevalent. The condition, caused by an inability of the eyes to produce enough quality tears, results…
